KR20180070609A - 렙틴 수용체를 활성화하는 항원-결합 단백질 - Google Patents

렙틴 수용체를 활성화하는 항원-결합 단백질 Download PDF

Info

Publication number
KR20180070609A
KR20180070609A KR1020187013185A KR20187013185A KR20180070609A KR 20180070609 A KR20180070609 A KR 20180070609A KR 1020187013185 A KR1020187013185 A KR 1020187013185A KR 20187013185 A KR20187013185 A KR 20187013185A KR 20180070609 A KR20180070609 A KR 20180070609A
Authority
KR
South Korea
Prior art keywords
lepr
antibody
antigen
binding fragment
leptin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187013185A
Other languages
English (en)
Korean (ko)
Inventor
제스퍼 그로마다
파나이오티스 스테비스
주디스 알타레조스
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57184864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20180070609(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Priority to KR1020257014408A priority Critical patent/KR20250069979A/ko
Publication of KR20180070609A publication Critical patent/KR20180070609A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020187013185A 2015-10-12 2016-10-11 렙틴 수용체를 활성화하는 항원-결합 단백질 Ceased KR20180070609A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257014408A KR20250069979A (ko) 2015-10-12 2016-10-11 렙틴 수용체를 활성화하는 항원-결합 단백질

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562240021P 2015-10-12 2015-10-12
US62/240,021 2015-10-12
US201662359757P 2016-07-08 2016-07-08
US62/359,757 2016-07-08
US201662375495P 2016-08-16 2016-08-16
US62/375,495 2016-08-16
US201662393143P 2016-09-12 2016-09-12
US62/393,143 2016-09-12
PCT/US2016/056465 WO2017066204A1 (en) 2015-10-12 2016-10-11 Antigen-binding proteins that activate the leptin receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257014408A Division KR20250069979A (ko) 2015-10-12 2016-10-11 렙틴 수용체를 활성화하는 항원-결합 단백질

Publications (1)

Publication Number Publication Date
KR20180070609A true KR20180070609A (ko) 2018-06-26

Family

ID=57184864

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187013185A Ceased KR20180070609A (ko) 2015-10-12 2016-10-11 렙틴 수용체를 활성화하는 항원-결합 단백질
KR1020257014408A Pending KR20250069979A (ko) 2015-10-12 2016-10-11 렙틴 수용체를 활성화하는 항원-결합 단백질

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257014408A Pending KR20250069979A (ko) 2015-10-12 2016-10-11 렙틴 수용체를 활성화하는 항원-결합 단백질

Country Status (32)

Country Link
US (6) US10023644B2 (enExample)
EP (2) EP3362477B1 (enExample)
JP (5) JP7034068B2 (enExample)
KR (2) KR20180070609A (enExample)
CN (1) CN108368177B (enExample)
AU (2) AU2016338851B2 (enExample)
BR (1) BR112018007318A2 (enExample)
CA (1) CA3000215A1 (enExample)
CL (2) CL2018000946A1 (enExample)
CO (1) CO2018003852A2 (enExample)
CY (1) CY1125102T1 (enExample)
DK (1) DK3362477T3 (enExample)
EA (1) EA201890928A1 (enExample)
ES (1) ES2908574T3 (enExample)
HR (1) HRP20220426T8 (enExample)
HU (1) HUE058280T2 (enExample)
IL (3) IL316563A (enExample)
LT (1) LT3362477T (enExample)
MX (2) MX2018004531A (enExample)
MY (1) MY187975A (enExample)
PH (1) PH12018500663A1 (enExample)
PL (1) PL3362477T3 (enExample)
PT (1) PT3362477T (enExample)
RS (1) RS63061B1 (enExample)
SG (1) SG10201913432RA (enExample)
SI (1) SI3362477T1 (enExample)
SM (1) SMT202200125T1 (enExample)
TW (3) TW202417497A (enExample)
UA (1) UA124419C2 (enExample)
UY (1) UY36942A (enExample)
WO (1) WO2017066204A1 (enExample)
ZA (1) ZA201801975B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202417497A (zh) * 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
CN110167965A (zh) 2016-11-08 2019-08-23 瑞泽恩制药公司 拮抗瘦素受体的抗原结合蛋白
ES2919934T3 (es) 2017-05-05 2022-07-29 Regeneron Pharma Autoinyector y procedimientos de uso relacionados
MX2020006508A (es) * 2017-12-18 2020-09-17 Regeneron Pharma Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas.
JP7420730B2 (ja) 2018-04-06 2024-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体
MY203367A (en) * 2018-10-11 2024-06-26 Sumitomo Chemical Co Propylene oxide purification system and method for producing propylene oxide
US12404346B2 (en) 2019-01-31 2025-09-02 Siemens Healthcare Diagnostics Inc. Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof
US20220288169A1 (en) * 2019-05-24 2022-09-15 The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College Compositions and methods for the treatment and prevention of hypoglycemic complications
KR20220029705A (ko) * 2019-07-02 2022-03-08 상하이테크 유니버시티 렙틴 수용체에 대한 항체
CN114746848B (zh) 2019-12-03 2023-08-04 美光科技公司 用于存储装置的高速缓存架构
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2021343444A1 (en) * 2020-09-15 2023-04-20 Regeneron Pharmaceuticals, Inc. Use of lepr agonists for pain
DK4294257T3 (da) 2021-02-22 2025-12-08 Regeneron Pharma Fremgangsmåde til diagnosticering og behandling af partiel lipodystrofi
CN114456124B (zh) * 2021-12-30 2023-04-21 华南农业大学 一种新利司他半抗原、人工抗原、抗体及其制备方法和应用
WO2024259313A1 (en) 2023-06-16 2024-12-19 Regeneron Pharamceuticals, Inc. Medical device packaging and related methods
AR134008A1 (es) 2023-10-02 2025-11-26 Regeneron Pharma Sistema de seguridad de dispositivo de administración de fármaco
JP2025148269A (ja) 2024-03-15 2025-10-07 イーライ リリー アンド カンパニー 肥満を治療するための単独又は併用療法としてのレプチン受容体アゴニスト抗体
WO2025227054A1 (en) * 2024-04-25 2025-10-30 The Board Of Regents Of The University Of Texas System Monoclonal antibodies binding to leptin and uses thereof
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US5856098A (en) 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US6482927B1 (en) 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US6977240B1 (en) * 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US20020193571A1 (en) 1996-01-08 2002-12-19 Paul J. Carter Wsx receptor agonist antibodies
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
AU2476301A (en) 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
JP4018142B2 (ja) 1996-01-23 2007-12-05 インデバス ファーマシューティカルズ，インコーポレーテッド 造血発生を刺激するためのｏｂｅｓｅ遺伝子およびその産物の使用方法
AUPN780096A0 (en) 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US5965521A (en) 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
PL214862B1 (pl) 2001-10-22 2013-09-30 Amgen Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny
JP2005516001A (ja) 2001-12-05 2005-06-02 ベイラー カレッジ オブ メディスン 交感神経活動状態の調節による骨形成の制御のための方法及び組成物
FR2852397B1 (fr) 2003-03-10 2005-04-29 Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal.
DE10353593A1 (de) 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
WO2005056602A1 (ja) 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha アゴニスト活性を有する改変抗体のスクリーニング方法
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
US20100260772A1 (en) 2007-09-28 2010-10-14 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing diseases associated with low bone mass
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
EP3028565B1 (en) 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SMT201900372T1 (it) 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
TR201802772T4 (tr) 2010-11-17 2018-03-21 Chugai Pharmaceutical Co Ltd Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
AU2012215572A1 (en) 2011-02-10 2013-05-02 Roche Glycart Ag Improved immunotherapy
DK2813573T1 (da) 2011-02-25 2015-01-12 Regeneron Pharma ADAM6 mus
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
HUE068728T2 (hu) 2011-08-05 2025-01-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
SG11201407644UA (en) 2012-06-05 2014-12-30 Regeneron Pharma Methods for making fully human bispecific antibodies using a common light chain
ES2684549T3 (es) 2012-09-12 2018-10-03 Genzyme Corporation Polipéptidos que contienen Fc con glicosilación alterada y función efectora reducida
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
DK3108255T3 (da) 2014-02-18 2020-11-09 Inst Nat Sante Rech Med Fremgangsmåder og farmaceutiske sammensætninger til behandling af sygdomme medieret af nrp-1/obr-komplekssignalvejen
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
CN110167965A (zh) 2016-11-08 2019-08-23 瑞泽恩制药公司 拮抗瘦素受体的抗原结合蛋白
CN107760761A (zh) 2017-11-10 2018-03-06 江苏省农业科学院 一种加强瘦素激发lepr信号转导的方法
MX2020006508A (es) 2017-12-18 2020-09-17 Regeneron Pharma Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas.
JP7420730B2 (ja) 2018-04-06 2024-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体

Also Published As

Publication number Publication date
JP2021090461A (ja) 2021-06-17
CO2018003852A2 (es) 2018-07-10
MY187975A (en) 2021-11-05
ES2908574T3 (es) 2022-05-03
US20200031946A1 (en) 2020-01-30
NZ780754A (en) 2025-06-27
HRP20220426T1 (hr) 2022-05-27
US10253102B2 (en) 2019-04-09
NZ741097A (en) 2025-06-27
SG10201913432RA (en) 2020-03-30
CL2019001434A1 (es) 2019-10-11
IL258448A (en) 2018-05-31
US20170101477A1 (en) 2017-04-13
HRP20220426T8 (hr) 2022-06-10
LT3362477T (lt) 2022-03-10
PL3362477T3 (pl) 2022-05-02
SMT202200125T1 (it) 2022-05-12
US20180282421A1 (en) 2018-10-04
JP2024042114A (ja) 2024-03-27
US20250051465A1 (en) 2025-02-13
JP7165225B2 (ja) 2022-11-02
IL258448B1 (en) 2023-04-01
RS63061B1 (sr) 2022-04-29
WO2017066204A1 (en) 2017-04-20
JP2023002713A (ja) 2023-01-10
JP7436603B2 (ja) 2024-02-21
TWI824372B (zh) 2023-12-01
IL300961A (en) 2023-04-01
UA124419C2 (uk) 2021-09-15
TW202417497A (zh) 2024-05-01
JP7759417B2 (ja) 2025-10-23
JP2024026230A (ja) 2024-02-28
US10618968B2 (en) 2020-04-14
MX2018004531A (es) 2018-09-12
IL300961B1 (en) 2024-12-01
JP7699191B2 (ja) 2025-06-26
EA201890928A1 (ru) 2018-09-28
PH12018500663A1 (en) 2018-10-01
PT3362477T (pt) 2022-03-02
ZA201801975B (en) 2020-07-29
IL258448B2 (en) 2023-08-01
HK1254862A1 (zh) 2019-07-26
TW202216785A (zh) 2022-05-01
NZ780753A (en) 2025-06-27
AU2016338851B2 (en) 2023-08-10
CN108368177A (zh) 2018-08-03
SI3362477T1 (sl) 2022-04-29
BR112018007318A2 (en) 2018-10-23
JP2018535948A (ja) 2018-12-06
EP3362477B1 (en) 2022-01-05
CA3000215A1 (en) 2017-04-20
US20180282420A1 (en) 2018-10-04
TW201726737A (zh) 2017-08-01
CY1125102T1 (el) 2024-02-16
CL2018000946A1 (es) 2018-12-14
US20220112293A1 (en) 2022-04-14
JP7034068B2 (ja) 2022-03-11
UY36942A (es) 2017-05-31
CN108368177B (zh) 2022-05-31
KR20250069979A (ko) 2025-05-20
HUE058280T2 (hu) 2022-07-28
EP3362477A1 (en) 2018-08-22
DK3362477T3 (da) 2022-03-07
US10023644B2 (en) 2018-07-17
EP4071173A1 (en) 2022-10-12
AU2016338851A1 (en) 2018-04-19
AU2023206125A1 (en) 2023-08-31
US12275792B2 (en) 2025-04-15
MX2023000738A (es) 2023-02-13
IL300961B2 (en) 2025-04-01
IL316563A (en) 2024-12-01
TWI752920B (zh) 2022-01-21

Similar Documents

Publication Publication Date Title
US20250051465A1 (en) Antigen-binding proteins that activate the leptin receptor
KR102563568B1 (ko) 렙틴 수용체에 길항하는 항원-결합 단백질
HK40072673A (en) Antigen-binding proteins that activate the leptin receptor
HK1254862B (en) Antigen-binding proteins that activate the leptin receptor
EA041859B1 (ru) Антигенсвязывающие белки, которые активируют лептиновый рецептор
EA048830B1 (ru) Полинуклеотиды, кодирующие антитела, которые связываются с лептиновым рецептором, и способ получения таких антител

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180509

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211007

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230919

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240816

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20250224

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20250224

X601 Decision of rejection after re-examination